Innovent and Lilly's Tyvyt (sintilimab injection) + Gemcitabine and Platinum CT Receive NMPA's Approval as 1L Therapy for Squamous Non-Small Cell Lung Cancer
Shots:
- The approval is based on P-III ORIENT-12 trial evaluating Tyvyt (sintilimab injection) or PBO + Gemzar (gemcitabine) & platinum CT in 357 patients in a ratio (1:1) as 1L therapy for advanced or metastatic sqNSCLC
- Results: Improvement in PFS & OS- m-PFS (5.5 vs 4.9 mos.) as assessed by IRRC & (6.7 vs 4.9 mos.) as assessed by study's investigators- m-OS was not mature- safety is consistent with previous studies & no new safety signals were identified
- Sintilimab is an innovative PD-1 inhibitor & approval marks the 3rd indication for therapy. The company is currently conducting 20+ clinical studies of sintilimab for different types of cancer- includes 10+ registrational or clinical trials
Ref: PR Newswire | Image:Innovent
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com